We are live on ! Find out more
SLXP

SALIX PHARMACEUTICALS LTD DEL
SLXP

Delisted

SLXP was delisted on the 31st of March, 2015.

Back to rankings

1 hedge funds and large institutions have $52K invested in SALIX PHARMACEUTICALS LTD DEL in 2015 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 297 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 298 → 1 (-297)

100% less funds holding in top 10

Funds holding in top 10: 47 → 0 (-47)

100% less capital invested

Capital invested by funds: $10.8B → $52K (-$10.8B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 297

Holders
1
Holders Change
-297
Holders Change %
-99.66%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-47
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
297
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
PC
Paulson & Co
New York
-$950M
2
PCM
Pentwater Capital Management
Florida
-$652M
3
State Street
State Street
Massachusetts
-$376M
4
YCMGA
York Capital Management Global Advisors
New York
-$327M
5
BIT
BlackRock Institutional Trust
California
-$317M
Name Holding Trade Value Shares
Change 		Change in
Stake
MMG
1
Monetary Management Group
Missouri
$52K – – –
PC
2
Paulson & Co
New York
– -$950M -5,500,000 Closed
PCM
3
Pentwater Capital Management
Florida
– -$652M -3,771,200 Closed
State Street
4
State Street
Massachusetts
– -$376M -2,177,900 Closed
YCMGA
5
York Capital Management Global Advisors
New York
– -$327M -1,894,527 Closed
BIT
6
BlackRock Institutional Trust
California
– -$317M -1,833,367 Closed
BFA
7
BlackRock Fund Advisors
California
– -$303M -1,755,863 Closed
Goldman Sachs
8
Goldman Sachs
New York
– -$300M -1,733,556 Closed
FCM
9
Farallon Capital Management
California
– -$268M -1,552,600 Closed
Fidelity Investments
10
Fidelity Investments
Massachusetts
– -$264M -1,526,841 Closed
Vanguard Group
11
Vanguard Group
Pennsylvania
– -$249M -1,442,171 Closed
MCM
12
Mason Capital Management
New York
– -$239M -1,381,898 Closed
HP
13
Hound Partners
New York
– -$231M -1,336,259 Closed
SC
14
Sculptor Capital
New York
– -$214M -1,235,563 Closed
WIC
15
Water Island Capital
New York
– -$212M -1,225,712 Closed
TS
16
Twin Securities
New York
– -$206M -1,189,192 Closed
TAL
17
TIG Advisors LLC
New York
– -$187M -1,080,717 Closed
Renaissance Technologies
18
Renaissance Technologies
New York
– -$145M -840,943 Closed
Millennium Management
19
Millennium Management
New York
– -$145M -838,953 Closed
GF
20
Gabelli Funds
New York
– -$142M -822,185 Closed
Morgan Stanley
21
Morgan Stanley
New York
– -$140M -807,361 Closed
UOC
22
UBS O'Connor
Illinois
– -$136M -786,238 Closed
Invesco
23
Invesco
Georgia
– -$126M -726,443 Closed
SHCM
24
Sachem Head Capital Management
New York
– -$125M -725,000 Closed
Bank of New York Mellon
25
Bank of New York Mellon
New York
– -$118M -680,307 Closed
1
2 3 4 5

SLXP Hedge Fund Activity: Q2 2015 in Review

1 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in SALIX PHARMACEUTICALS LTD DEL (SLXP) for Q2 2015, worth a combined $52K — down 100% from $10.8B a quarter earlier.

Sellers outnumbered buyers: 297 funds closed out of SLXP and 0 opened new positions — a net loss of 297 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Paulson & Co, exiting entirely with an estimated $950M sold.

  • 1 institutional investor held SALIX PHARMACEUTICALS LTD DEL (SLXP) as of Q2 2015, down from 298 in Q1 2015.
  • Funds reported $52K of SALIX PHARMACEUTICALS LTD DEL stock for Q2 2015, down 100% quarter-over-quarter.
  • 0 funds opened new SALIX PHARMACEUTICALS LTD DEL positions in Q2 2015 and 297 closed out, a net change of -297 holders.
  • The largest SALIX PHARMACEUTICALS LTD DEL seller in Q2 2015 was Paulson & Co, an estimated $950M sold.

Based on aggregated 13F filings for Q2 2015.